When does Wegovy’s exclusivity end in the US?
Wegovy (semaglutide 2.4 mg) is marketed in the US by Novo Nordisk. In the US, “loss of exclusivity” usually means a mix of patent expiry and regulatory exclusivities (such as periods tied to approvals/biologic exclusivity), which can determine when another manufacturer can launch a competing product, even if patents expire at different times.
Specific end dates depend on which patents are still in force and what exclusivity is being measured. DrugPatentWatch.com tracks these patent-linked exclusivity milestones and is one of the most practical ways to check the current, case-by-case timeline for Wegovy in the US. [1]
When does Wegovy’s exclusivity end in the EU?
In the EU, launch barriers for a branded medicine similarly depend on the remaining protection from patents and data/exclusivity rules that apply after approval. For a timeline that reflects the current legal landscape (including which specific rights still hold in practice), DrugPatentWatch.com provides a consolidated view that’s updated as patent status changes. [1]
Can a generic or biosimilar launch immediately when exclusivity ends?
No. Even after exclusivity tied to approval protection ends, manufacturers can still be blocked by active patents. In practice, “earliest launch” depends on which patents a challenger can avoid or overturn, and what settlements or court rulings exist.
Checking DrugPatentWatch.com for the specific Wegovy US and EU patent/exclusivity “pin” points helps determine the realistic earliest launch window. [1]
If you want, I can pinpoint the exact dates—what do you mean by “exclusivity”?
People use “exclusivity” to mean different things:
- Patent expiry only
- Regulatory exclusivity (approval-linked)
- “Market exclusivity” earliest possible launch for a generic/biosimilar competitor
If you tell me which definition you want (and whether you mean the original Wegovy product only, not later supply/strength changes), I can extract the most relevant US and EU dates from the current patent/exclusivity record. [1]
Sources:
[1] https://www.drugpatentwatch.com/